Bulletin
Investor Alert

Market Pulse Archives

May 11, 2021, 7:33 a.m. EDT

Cerecor's investigational COVID-19 therapy gets Fast Track designation from the FDA

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

SPX

Shares of Cerecor Inc. gained 17.3% in premarket trading on Tuesday after the company said its experimental COVID-19 drug had received a Fast Track designation from the Food and Drug Administration. The treatment candidate is a monoclonal antibody being targeted at people with COVID-19 who are sick enough to be hospitalized. Cerecor's stock is down 3.8% for the year, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.91% is up 11.5%.

/zigman2/quotes/210599714/realtime
US : S&P US
4,432.99
-40.76 -0.91%
Volume: 3.79B
Sept. 17, 2021 5:25p
loading...

Get news alerts on S&P 500 Index — or create your own.
This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.